CM&D Pharma cmdpharmaltd.com


Public lists: Pharma Startups (4743)

CM&D was formed with the goal of establishing the first pan-European Specialty Pharma company focused on Foods for Special Medical Purposes (FSMPs). The company has acquired a range of marketed FSMPs and is developing FSMPs to treat a variety of medical conditions. These products benefit from being prescribable in the EU, and yet carry a much lower regulatory burden. This greatly reduces the time to market, regulatory and clinical trial requirements, and therefore the risk of failure to launch.

CM&D was formed with the goal of establishing the first pan-European Specialty Pharma company focused on Foods for Special Medical Purposes (FSMPs). The company has acquired a range of marketed FSMPs and is developing FSMPs to treat a variety of medi...Show all

Company (Acquired)

Phone: (+44) 207-259-0000

Fax: (+44) 207-259-8480

156-158 Buckingham Palace Road

SW1W 9TR
United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
CM&D Pharma $0M Feb 14, 2011
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related CM&D Pharma Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

ARYX Therapeutics

Fremont, California, United States
IPO / Went publicARYx Therapeutics is a privately-held pharmaceutical research and development company focused on addressing safety concerns in well-established and commercially successful existing therapies through application of its proprietary ARYx RetroMetabolic (ARM) drug design. ARYx improves today's drugs, making proven therapies safer. ARYx currently has three products in clinical trials. For more information, please see the company's web site at www.aryx.com.Login to see details

Trillium Therapeutics

Toronto, Ontario, Canada
IPO / Went publicTrillium Therapeutics is a research and development company developing therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses, including autoimmune and inflammatory disorders, graft rejection, cancer and chronic viral diseases.Login to see details
See all 16 competitors